Printed from BusinessInsurance.com

Cigna rejects costly ALS medication from coverage

Posted On: Feb. 9, 2023 9:59 AM CST

Cigna Corp. has changed its policy for a new and in-demand medicine for ALS, or amyotrophic lateral sclerosis, deciding not to cover it due to “a lack of clinical efficacy data,” Healthcare Dive reports. The drug Relyvrio, which Cigna called “experimental, investigational or unproven,” was developed by the Massachusetts-based biotechnology company Amylyx Pharmaceuticals and costs $158,000 per year.